Breckenridge settles with end-payers for $5.5m in US generic drug antitrust case
MLex Summary: Breckenridge Pharmaceutical agreed to pay $5.5 million to resolve end-payers’ US price-fixing allegations over generic drugs. The deal is subject to approval by a federal judge.See attached file. ...To view the full article, register now.
Already a subscriber? Click here to view full article